Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Choy, Cassandra
PROPEL 2, NCT04265651 / 2019-002954-21: Study of Infigratinib in Children with Achondroplasia	Active, not recruiting	2	84	Europe, Canada, US, RoW	Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg, Infigratinib 0.128 mg/kg, Infigratinib 0.25 mg/kg	QED Therapeutics, Inc.	Achondroplasia	10/24	12/24
NCT05145010 / 2021-001855-15: Extension Study of Infigratinib in Children with Achondroplasia (ACH)	Enrolling by invitation	2	300	Europe, Canada, US, RoW	Infigratinib	QED Therapeutics, Inc., QED Therapeutics, Inc.	Achondroplasia	12/31	02/32
PROPEL, NCT04035811: Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)	Recruiting	N/A	250	Europe, Canada, US, RoW		QED Therapeutics, Inc.	Achondroplasia	06/26	06/26